BR112023002234A2 - Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 - Google Patents
Anticorpos sars-cov-2 para tratamento e prevenção de covid-19Info
- Publication number
- BR112023002234A2 BR112023002234A2 BR112023002234A BR112023002234A BR112023002234A2 BR 112023002234 A2 BR112023002234 A2 BR 112023002234A2 BR 112023002234 A BR112023002234 A BR 112023002234A BR 112023002234 A BR112023002234 A BR 112023002234A BR 112023002234 A2 BR112023002234 A2 BR 112023002234A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- covid
- cov
- sars
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063862P | 2020-08-10 | 2020-08-10 | |
| US202063112104P | 2020-11-10 | 2020-11-10 | |
| PCT/EP2021/072203 WO2022034044A1 (en) | 2020-08-10 | 2021-08-09 | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002234A2 true BR112023002234A2 (pt) | 2023-03-07 |
Family
ID=77595513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002234A BR112023002234A2 (pt) | 2020-08-10 | 2021-08-09 | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220041694A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4192860A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023537078A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230045613A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116234577A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021325339A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023002234A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190280A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300257A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202221025A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022034044A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021195418A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Rq生物科技有限公司 | 抗體 |
| CR20240528A (es) | 2022-04-29 | 2025-04-04 | Astrazeneca Uk Ltd | Anticuerpos contra el sars-cov-2 y métodos para utilizarlos |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| CA2923247A1 (en) | 2002-03-19 | 2003-09-25 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
| KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
| EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| CN102387814A (zh) | 2009-01-29 | 2012-03-21 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| CN106604744A (zh) * | 2014-09-03 | 2017-04-26 | 免疫医疗有限公司 | 稳定的抗IL‑4R‑α抗体配制品 |
| WO2021195418A1 (en) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| PH12022553106A1 (en) * | 2020-05-17 | 2023-11-20 | Astrazeneca Uk Liimited | Sars-cov-2-antibodies and methods of selecting and using the same |
-
2021
- 2021-08-09 IL IL300257A patent/IL300257A/en unknown
- 2021-08-09 KR KR1020237008224A patent/KR20230045613A/ko active Pending
- 2021-08-09 CN CN202180056725.0A patent/CN116234577A/zh active Pending
- 2021-08-09 US US17/397,203 patent/US20220041694A1/en not_active Abandoned
- 2021-08-09 JP JP2023509418A patent/JP2023537078A/ja active Pending
- 2021-08-09 BR BR112023002234A patent/BR112023002234A2/pt unknown
- 2021-08-09 TW TW110129325A patent/TW202221025A/zh unknown
- 2021-08-09 AU AU2021325339A patent/AU2021325339A1/en not_active Abandoned
- 2021-08-09 EP EP21763274.4A patent/EP4192860A1/en not_active Withdrawn
- 2021-08-09 WO PCT/EP2021/072203 patent/WO2022034044A1/en not_active Ceased
- 2021-08-09 CA CA3190280A patent/CA3190280A1/en active Pending
-
2023
- 2023-08-09 US US18/446,782 patent/US20240092875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW202221025A (zh) | 2022-06-01 |
| IL300257A (en) | 2023-03-01 |
| AU2021325339A1 (en) | 2023-04-06 |
| US20220041694A1 (en) | 2022-02-10 |
| CN116234577A (zh) | 2023-06-06 |
| CA3190280A1 (en) | 2022-02-17 |
| EP4192860A1 (en) | 2023-06-14 |
| WO2022034044A1 (en) | 2022-02-17 |
| JP2023537078A (ja) | 2023-08-30 |
| KR20230045613A (ko) | 2023-04-04 |
| US20240092875A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000705A1 (es) | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno | |
| BR112023016580A2 (pt) | Anticorpos anti-tcr delta variáveis 1 | |
| BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
| DOP2024000207A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| BR112022018949A2 (pt) | Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2) | |
| BR112022024149A2 (pt) | Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| BR112017026189A2 (pt) | tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4 | |
| BR112021021713A2 (pt) | Método de tratamento de câncer ou inibição do crescimento de um tumor | |
| CY1111958T1 (el) | Θεραπευτικη χρηση αντισωματων anti-csi | |
| BRPI0506726B8 (pt) | anticorpo monoclonal específico para m-csf e usos deste | |
| BR112024000744A2 (pt) | Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno | |
| PH12022500028A1 (en) | Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies | |
| MX2024009860A (es) | Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus | |
| BR112022024361A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| ATE552852T1 (de) | Zusammensetzungen und verfahren zur behandlung von virusinfektionen | |
| BR112023016680A2 (pt) | Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina | |
| JOP20210159A1 (ar) | أجسام مضادة لـ pmel17 ومترافقات منها | |
| BR112022011350A2 (pt) | Composições e métodos para tratamento e prevenção da influenza | |
| BR112023023558A2 (pt) | Anticorpos anti-tmprss6 e usos dos mesmos | |
| MX2022001626A (es) | Composiciones biofarmaceuticas y procedimientos conexos. | |
| BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos | |
| CL2025003288A1 (es) | Anticuerpos que se unen a ox40l y métodos de uso. | |
| BR112022014278A2 (pt) | Conjugados de composto proteico-antiviral | |
| BR112021024401A2 (pt) | Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 5A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCEDER COM:? PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PEDIDO.? PAGAMENTO DE 1 (UMA) GRU, SERVICO 221, REFERENTE(S) A(S) ANUIDADE(S) EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96. CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, ATRA |